Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0106213793
Tue, 05.11.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, 4 November 2024
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it expects the Swiss SIX exch [ … ]
Mon, 29.07.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, 29 July 2024
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focuse [ … ]
Mon, 22.07.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, 22 July 2024
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on m [ … ]
Mon, 08.07.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, 8 July, 2024
PARI Pharma GmbH announces termination of ColiFin® license to EnBiotix, Inc.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that PARI Pharma GmbH (“PARI”), the owne [ … ]
Tue, 04.06.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, June 4, 2024
Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that the company [ … ]
Tue, 04.06.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, June 4, 2024
Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that the company [ … ]
Fri, 31.05.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, May 31, 2024
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company [ … ]
Tue, 30.04.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 30, 2024
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for ra [ … ]
Tue, 30.04.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 30, 2024
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for ra [ … ]
Wed, 17.04.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 17, 2024
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
The Western District Court of the Canton Basel-Landschaft has granted Spexis [ … ]